reports
- Keith Hiscock
- Mark Thomas
- Martin Hall
- Mike Foster
The Hardman & Co Monthly: September 2022
Feature article: Macro issues dominate investor sentiment - Some basics for investors The big topics in the investment world at the moment seem to be macroeconomic. With that in mind, we thought it would be useful to revisit some of the basics of the terms being used in the current environment, and to remind investors of the things to look out for (indeed, many younger investors may not have come across some of these influences in their investing lifetime): • Recession does not affect ...
FEV FIDELITY EUROPEAN VALUES PLC
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FSV FIDELITY SPECIAL VALUES PLC
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
AVO ADVANCED ONCOTHERAPY
RECI REAL ESTATE CREDIT INVESTMENTS
APP APPRECIATE GROUP
PANR PANTHEON RESOURCES
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
OCI OAKLEY CAPITAL INVESTMENTS
DNL DIURNAL GROUP
ICGT ICG ENTERPRISE TRUST
CIZ CIZZLE BIOTECHNOLOGY HLDGS PLC
OCL OAKLEY CAPITAL
- Brian Moretta
- Mark Thomas
- Martin Hall
- Mike Foster
- Nigel Hawkins
The Hardman & Co Monthly: August 2022
Feature article: Utility regulation – Changes afoot - Patching up a tainted model While the gas supply crisis – and its price implications – have dominated the UK price regulated sectors in recent months, other issues have arisen that have seriously tainted the price regulation system itself. Indeed, it is fair to ask whether it is ‘’fit for purpose’’. Back in 1984, price regulation, via an unsophisticated RPI-x formula, was introduced to prevent the privatised British Telecom (BT) from abusin...
FEV FIDELITY EUROPEAN VALUES PLC
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
CLIG CITY OF LONDON INVESTMENT GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
APP APPRECIATE GROUP
PANR PANTHEON RESOURCES
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
OCI OAKLEY CAPITAL INVESTMENTS
DNL DIURNAL GROUP
PCA PALACE CAPITAL
ICGT ICG ENTERPRISE TRUST
BBGI BBGI GLOBAL INFRASTRUCTURE
CIZ CIZZLE BIOTECHNOLOGY HLDGS PLC
OCL OAKLEY CAPITAL
Hardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progre...
Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progress in first year since listing 11-Jul-2022 / 07:15 GMT/BST Hardman & Co Research on Cizzle Biotechnology (CIZ): Considerable progress in first year since listing Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy over the past year, Cizzle’s interest has been broadened to include early detection of other canc...
- Martin Hall
Hardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progre...
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy over the past year, Cizzle’s interest has been broadened to include early detection of other cancers and companion diagnostic tests that can assist in the development and use of personalised medicines. In the 12 months since listing, Cizzle has secured key partners ...
- Brian Moretta
- Mark Thomas
- Martin Hall
- Mike Foster
- Nigel Hawkins
Hardman & Co Monthly: April 2022
An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2021, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2021. Comparisons are made with historical data to show how different company strategies have evolved. 2021 was characterised by a strong rebound in performance following the pandemic-aff...
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FSV FIDELITY SPECIAL VALUES PLC
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
AVO ADVANCED ONCOTHERAPY
CLIG CITY OF LONDON INVESTMENT GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
APP APPRECIATE GROUP
PANR PANTHEON RESOURCES
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
OCI OAKLEY CAPITAL INVESTMENTS
PCA PALACE CAPITAL
ICGT ICG ENTERPRISE TRUST
BBGI BBGI GLOBAL INFRASTRUCTURE
CIZ CIZZLE BIOTECHNOLOGY HLDGS PLC
OCL OAKLEY CAPITAL
- Martin Hall
Cizzle Biotechnology (CIZ) Strategic alliance in China
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. Cizzle has converted a mem...
Hardman & Co Research: Cizzle Biotechnology (CIZ) Strategic alliance i...
Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ) Strategic alliance in China 08-Feb-2022 / 12:15 GMT/BST Hardman & Co Research: Strategic alliance in China Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false pos...
Hardman & Co Research: Cizzle Biotechnology (CIZ): News flow driven by...
Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ): News flow driven by deals 07-Dec-2021 / 11:50 GMT/BST Hardman & Co Research: News flow driven by deals Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test that allows early detection of lung cancer and potentially improve patient outcomes. Since listing, Cizzle has been considering how to develop a broader screening t...
Hardman & Co Research: Cizzle Biotechnology/Bould (CIZ): Early detecti...
Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology/Bould (CIZ): Early detection of lung cancer 14-May-2021 / 10:50 GMT/BST Hardman & Co Research: (Initiation of coverage) Early detection of lung cancer Cizzle Biotechnology Ltd (Cizzle) was identified by Bould Opportunities (Bould) as its preferred target for a reverse takeover. Cizzle is a spin-out from the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. The presence of nodules often detected on chest scans is suspicious, but not usually a sign of lun...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.